by secretome | Mar 25, 2025 | News
PLANO, Texas & BALTIMORE–(BUSINESS WIRE)–Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced dosing of the first patient in its Phase 1...
by secretome | Mar 20, 2025 | News
DALLAS–(BUSINESS WIRE)–Secretome Therapeutics, a pioneering company in the field of regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to STM-01, the company’s neonatal cardiac...
by secretome | Jan 22, 2025 | News
THE WOODLANDS, Texas and DALLAS, Jan. 22, 2025 /PRNewswire/ — Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome Therapeutics, a biotechnology company advancing...
by secretome | Nov 25, 2024 | News
DALLAS–(BUSINESS WIRE)–Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the successful closing of a $20.4 million round of financing. This funding will enable...
by secretome | Oct 28, 2024 | Investors, News
DALLAS–(BUSINESS WIRE)–Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the allowance of a composition of matter patent for its lead asset, STM-01, a novel nCPC...
by secretome | Sep 17, 2024 | News
DALLAS, Sept. 17, 2024 /PRNewswire/ — HEST Investments, a Dallas-based venture capital family office renowned for its focus on innovative and bleeding edge ventures, proudly announces its successful SPV (Special Purpose Vehicle) of...
